Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias

TY - JOUR

T1 - Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias

AU - Bachmann, C G

AU - Zapf, A

AU - Brunner, E

AU - Trenkwalder, C

PY - 2009/8

Y1 - 2009/8

N2 - BACKGROUND AND PURPOSE: Several studies suggested that patients with advanced Parkinson's disease (PD) showed a too low body weight when compared with age-matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants.METHODS: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson's Disease Rating Scale motor score, eating coordination and medication.RESULTS: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m(2)), 46.4% were normal (BMI > 18.5-25 kg/m(2)), 33.7% were overweight (BMI > 25-30 kg/m(2)), 15.7% were obese (BMI > 30 kg/m(2)). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients' BMI had not significantly changed within 2 years of follow-up.CONCLUSIONS: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age-matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.

AB - BACKGROUND AND PURPOSE: Several studies suggested that patients with advanced Parkinson's disease (PD) showed a too low body weight when compared with age-matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants.METHODS: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson's Disease Rating Scale motor score, eating coordination and medication.RESULTS: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m(2)), 46.4% were normal (BMI > 18.5-25 kg/m(2)), 33.7% were overweight (BMI > 25-30 kg/m(2)), 15.7% were obese (BMI > 30 kg/m(2)). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients' BMI had not significantly changed within 2 years of follow-up.CONCLUSIONS: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age-matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.

KW - Age of Onset

KW - Aged

KW - Antiparkinson Agents

KW - Body Mass Index

KW - Body Weight

KW - Dopamine Agents

KW - Dyskinesias

KW - Eating

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Levodopa

KW - Male

KW - Middle Aged

KW - Parkinson Disease

KW - Psychomotor Performance

KW - Severity of Illness Index

KW - Time Factors

KW - Weight Loss

KW - Journal Article

U2 - 10.1111/j.1468-1331.2009.02617.x

DO - 10.1111/j.1468-1331.2009.02617.x

M3 - SCORING: Journal article

C2 - 19374662

VL - 16

SP - 895

EP - 901

JO - EUR J NEUROL

JF - EUR J NEUROL

SN - 1351-5101

IS - 8

ER -